JP2022513798A5 - - Google Patents

Info

Publication number
JP2022513798A5
JP2022513798A5 JP2021533535A JP2021533535A JP2022513798A5 JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5 JP 2021533535 A JP2021533535 A JP 2021533535A JP 2021533535 A JP2021533535 A JP 2021533535A JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5
Authority
JP
Japan
Application number
JP2021533535A
Other languages
Japanese (ja)
Other versions
JP2022513798A (ja
JPWO2020124032A5 (https=
JP7664158B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066376 external-priority patent/WO2020124032A1/en
Publication of JP2022513798A publication Critical patent/JP2022513798A/ja
Publication of JP2022513798A5 publication Critical patent/JP2022513798A5/ja
Publication of JPWO2020124032A5 publication Critical patent/JPWO2020124032A5/ja
Priority to JP2024214382A priority Critical patent/JP2025038018A/ja
Application granted granted Critical
Publication of JP7664158B2 publication Critical patent/JP7664158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533535A 2018-12-14 2019-12-13 トランスフェリン受容体標的ペプチド Active JP7664158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024214382A JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779885P 2018-12-14 2018-12-14
US62/779,885 2018-12-14
US201962836520P 2019-04-19 2019-04-19
US62/836,520 2019-04-19
PCT/US2019/066376 WO2020124032A1 (en) 2018-12-14 2019-12-13 Transferrin receptor targeting peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024214382A Division JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Publications (4)

Publication Number Publication Date
JP2022513798A JP2022513798A (ja) 2022-02-09
JP2022513798A5 true JP2022513798A5 (https=) 2022-12-20
JPWO2020124032A5 JPWO2020124032A5 (https=) 2022-12-20
JP7664158B2 JP7664158B2 (ja) 2025-04-17

Family

ID=71077078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533535A Active JP7664158B2 (ja) 2018-12-14 2019-12-13 トランスフェリン受容体標的ペプチド
JP2024214382A Pending JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024214382A Pending JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Country Status (8)

Country Link
US (1) US20220048961A1 (https=)
EP (1) EP3893913B1 (https=)
JP (2) JP7664158B2 (https=)
CN (1) CN113329758A (https=)
AU (1) AU2019398467A1 (https=)
CA (1) CA3120466A1 (https=)
IL (1) IL283839A (https=)
WO (1) WO2020124032A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN111647048B (zh) * 2020-06-22 2021-04-02 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
US12076364B2 (en) 2020-06-22 2024-09-03 Kunming Institute Of Zoology, Chinese Academy Of Sciences Use of interference peptide in preparation of anti-SARS-CoV-2 medicament
JP2022014707A (ja) * 2020-07-07 2022-01-20 東亞合成株式会社 キャリアペプチドフラグメントおよびその利用
CN116075524A (zh) * 2020-07-30 2023-05-05 华盛顿大学 转铁蛋白受体结合蛋白
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules
WO2022180628A1 (en) * 2021-02-23 2022-09-01 Ichilov Tech Ltd. Fusion proteins for treating cns diseases
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023023031A2 (en) * 2021-08-17 2023-02-23 Blaze Bioscience, Inc. Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
JPWO2023022234A1 (https=) * 2021-08-19 2023-02-23
CN118556069A (zh) * 2021-10-01 2024-08-27 首尔大学校产学协力团 用于穿透血脑屏障的肽及其用途
CN118139896A (zh) * 2021-10-15 2024-06-04 南通壹宸生物医药科技有限公司 一种双特异性结合分子
CN115160408B (zh) * 2022-06-29 2025-04-22 辽宁天增祥生物科技有限公司 降压肽或中国蛤蜊降压肽提取物及其应用
CN115925981B (zh) * 2022-08-18 2025-05-23 河南工业大学 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用
EP4626906A1 (en) * 2022-11-29 2025-10-08 Vacino Biotech Co., Ltd. Transporter peptides and application thereof
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
WO2024238304A2 (en) * 2023-05-12 2024-11-21 University Of Washington Improved transferrin receptor binding proteins
AU2024329222A1 (en) * 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025096245A1 (en) * 2023-11-02 2025-05-08 The Regents Of The University Of California Design rules for endosomal escape
CN120647772A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 特异性结合转铁蛋白受体的多肽及其应用
CN120459270A (zh) * 2025-05-16 2025-08-12 中国人民解放军海军军医大学 OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743893B2 (en) * 2000-11-30 2004-06-01 The Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
WO2004062602A2 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
CA2864126A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
AU2013266611B2 (en) * 2012-05-21 2016-08-11 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
WO2016077840A2 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
MX391086B (es) * 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
CA3033082A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)